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Background: It has been hypothesized that airway hyperresponsiveness (AHR) is characterized
by sensitivity (strength of stimulus) and reactivity (responsiveness to stimulus); the latter
could be the intrinsic characteristic of AHR. The underlying mechanisms leading to AHR could
be 1) airway inflammation, 2) reduction of forces opposing bronchoconstriction, and 3) struc-
tural airway changes/geometric factors.
Objective: Our main objective was to assess the relationships between reactivity in patients
with nasal polyposis and these three mechanisms using measurements of 1) bronchial and bron-
chiolar/alveolar NO, 2) bronchomotor response to deep inspiration, and 3) forced expiratory
flows and an index of airway to lung size, i.e. FEF25e75%/FVC.
Methods: Patients underwent spirometry, multiple flow measurement of exhaled NO (cor-
rected for axial diffusion), assessment of bronchomotor response to deep inspiration by forced
oscillation technique and methacholine challenge allowing the calculation of reactivity (slope
of the doseeresponse curve) and sensitivity (PD10).
Results: One hundred and thirty-two patients were prospectively enrolled of whom 71 exhib-
ited AHR. Airway reactivity was correlated with alveolar NO concentration (rho Z 0.35;
p Z 0.017), with airflow limitation (FEF25e75%: rho Z 0.40; p Z 0.003) and with an index
of airway size to lung size (FEF25e75%/FVC: rho Z 0.38; p Z 0.005), of which only alveolar
NO remained the only independent factor in a stepwise multiple regression analysis (variance
25%). Airway sensitivity was not correlated with any pulmonary function or exhaled NO param-
eter.Respiratoire e Clinique de la Dyspne´e, Hoˆpital Europe´en Georges Pompidou, 20, rue Leblanc, 75015
.
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Alveolar NO and airway reactivity 69Conclusion: In patients with nasal polyposis, alveolar NO is associated with airway reactivity,
suggesting that bronchiolar/alveolar lung inflammation may constitute one intrinsic character-
istic of increased responsiveness.
ª 2011 Elsevier Ltd. All rights reserved.Figure 1 Sequence of investigations. The bronchomotor
effect of deep inspiration (DI) is of short duration (median 65 s
[range, 35e120 s]) as previously demonstrated.8Introduction
Airway hyperresponsiveness (AHR), the tendency of the
airways to narrow too much and too easily in response to
various stimuli, is a universal feature of asthma, although it
is not exclusive to this disease. Airway inflammation and
structural airway changes can lead to this heightened
airway response. Accordingly with these statements made
by Boulet,1 inflammation and structural changes might be
associated with a change in smooth muscle mechanical
properties and/or a reduction of forces opposing broncho-
constriction, such as reduced airway-parenchymal inter-
dependence. Other factors, such as "geometric factors" (eg,
airway caliber related to lung size), can also modulate the
degree of AHR.2 Nevertheless, the mechanisms by which all
these potential factors modify airway function are still
unclear. The two major functional components of AHR are
airway reactivity and sensitivity, which can be obtained
from a doseeresponse curve to methacholine. Accordingly
to Sterk and Bel, reactivity could constitute the intrinsic
characteristic of AHR (responsiveness of the airways to
stimulus), while sensitivity could be related to extrinsic
factors as allergic exposure (strength of triggering stim-
ulus).3 Consequently, one may hypothesize that the rela-
tionships between reactivity/sensitivity and the potential
modifiers of AHR deserve to be studied.
Although the increase in exhaled NO commonly observed
in atopic subjects with or without symptoms has classically
been attributed to eosinophilic inflammation (one dimen-
sion of asthma), the relationships between fractional
exhaled NO (FENO) and both AHR
4 and bronchodilator
response5 suggest a specific link between NO and another
dimension of asthma, namely an increased airway tone.
Consequently, one may also hypothesize that a link
between exhaled NO and airway reactivity would be evi-
denced in patients with AHR. For this demonstration, par-
titioning of exhaled NO in its bronchial and bronchiolar/
alveolar origins is mandatory since a single expiratory flow
measurement at 50 mL/s mainly reflects the bronchial
contribution to FENO,
6 which is mainly linked to bronchial
inflammation,7 while alveolar NO should better represent
airway responsiveness.8,9
The aim of our cross-sectional physiological study was to
assess the relationships between airway reactivity/sensi-
tivity and 1) bronchial/alveolar NO origins (using multiple
flow exhaled NO measurement), 2) reduction of forces
opposing bronchoconstriction (using bronchomotor
response to deep inspiration [DI]), 3) structural airway
changes/geometric factors (using forced expiratory flows
and a crude assessment of airway to lung size, i.e.
FEF25e75%/FVC).
2,10 These three pathophysiological factors
were chosen because they may constitute three dimensions
of airway hyperresponsiveness accordingly to Boulet,1 even
if there is some links between them.Patients with nasal polyposis were enrolled because the
prevalence of non atopic asthma is elevated, which may
favour the discrimination of the role of NO that is not
associated with allergic inflammation.
Patients and methods
Design
All consecutive patients suffering from nasal polyposis
(diagnosis based on endoscopic examination and on
computed tomography, as previously described 10) referred
for baseline pulmonary function testing were eligible with
the exception of those suffering from another respiratory
disease than asthma or from a severe cardiac disease.
Patients were divided according to the presence of AHR,
and further divided in symptomatic (asthmatic) and
asymptomatic subjects. Our patient database has been
declared to our regulatory agency for computer data
collection (Commission Nationale Informatique et Liberte´s,
n 1391593v0), and approval from our local Ethics
Committee was obtained. All patients were informed of the
prospective recording of clinical and physiological data.
Diagnosis of confirmed asthma
The diagnosis of confirmed asthma was based on the fact
that symptoms of recurrent episodes of airflow obstruction
and AHR (based on PD20) were both present, and alternative
diagnoses were excluded, as recommended by GINA
guidelines.
Pulmonary function tests
The tests were conducted in the following order and are
summarized in Fig. 1.
Exhaled nitric oxide measurements
Exhaled NO was measured using a chemiluminescent nitric
oxide analyser (ENDONO 8000, Seres, Aix en Provence,
France) before performing spirometry (Fig. 1). Maximum
70 B. Mahut et al.conducting airway flux of NO (J’awNO) and bronchiolar/
alveolar NO concentration (CalvNO) were calculated after
obtaining several exhaled NO measurements at different
expiratory flow rates, using the previously described linear
approach.11 We used a validity criterion of this linear
approach.11 Then, NO exchange parameters were corrected
for axial NO back diffusion according to the method of
Condorelli and colleagues.12
Forced oscillation technique measurement of
bronchomotor response to deep inhalation
Respiratory impedance was determined using the standard
forced oscillation technique (Oscilink; Datalink-MSR, Run-
gis, France) according to recommendations.13 The real
component of respiratory impedance [resistance of the
respiratory system (Rrs)] was subjected to linear regression
analysis to obtain the intercept (R0, resistance extrapo-
lated to 0 Hz). The effect of three deep inspirations was
calculated as 100*(R0 after inspiration - R0 before inspira-
tion)/R0 before inspiration, as previously described.10 A
positive result indicates a bronchoconstrictor effect of
deep inhalation.
Spirometry and methacholine inhalation challenge
These tests (using MasterScreen Body, Jaeger, CareFusion)
were conducted according to international recommenda-
tions.14,15 Anti-asthma drugs were withheld according to
recommendations.14 Non-specific airway responsiveness to
methacholine was measured using successive doses from 0.05
to 2.4 mg (0.05, 0.20, 0.40, 0.80, 1.6 and 2.4 mg), delivered
using a nebulization dosimeter (Aero Doseur Atomisor, Diffu-
sion Technique Franc¸aise, Saint-Etienne, France) as previ-
ously described.10 The test was stopped if there was a 20%
decline in forced expiratory volume at 1 s (FEV1) from the
control value or if the maximum cumulative dose had been
reached. The change in FEV1 as a percentage of the reference
value has been plotted on the ordinate against the log
concentration on the abscissa. In patients with AHR, PD20 and
PD10 (sensitivity) were calculated using interpolation (after
log-linear regression), and the slope of the doseeresponse
curve defined reactivity. Reference values for spirometry
were those of Stanojevic and colleagues.16
Statistical analysis
Values are expressed as mean  SD or median [interquartile
range] as appropriate. Between groups comparisons used
Student-t test, except when stated. Correlations were eval-
uated using Spearman’s rank correlation coefficient. The
association between the different explanatory variables and
the dependent variable was examined in a multiple linear
regression model using the procedure for general linear
models (with log-transformed values for non normally
distributed variables). The multivariate analysis was per-
formed with a backward selection method and variables with
P values of less than 0.10were retained in the FENOmodel.We
further performed a multivariable logistic regression analysis
to evaluate AHR pathophysiology. Since our main aim was
restricted to patients with AHRwe decided to include at least120 patients with nasal polyposis in order to have a groupwith
AHR > 50 (based on the prevalence of AHR in this setting 10),
allowing multivariate analyses including a maximum of four
independent variables (10e15 patients/variable). Statistical
significancewas definedasP< 0.05. Datawereanalysedusing
Statview 5.0 (SAS Institute, Berkeley, CA, USA).
Results
The characteristics of the 132 patients enrolled are
described in Table 1. Seventy-one patients exhibited AHR.
These patients, as compared to those exhibiting no AHR,
had an increased alveolar NO concentration, increased
constrictor response to DI and a lower lung function.
Relationships between airway reactivity/sensitivity
and potential dimensions of AHR
Airway reactivity was correlated with alveolar NO concen-
tration (Fig. 2), with airflow limitation (FEF25e75%:
rho Z 0.40; p Z 0.003), with an index of airway size to
lung size (FEF25e75%/FVC: rho Z 0.38; p Z 0.005), and
was not correlated with response to DI (p Z 0.23).
Airway sensitivity was not correlated with any pulmo-
nary function or exhaled NO parameter.
PD20 was not significantly correlated with FENO0.05,
alveolar NO and bronchial NO.
We then assessed whether the third potential dimension
of AHR (response to DI) was linked to another dimension of
AHR. The bronchomotor effect of DI was correlated with
structural airway changes/geometric factor index (airflow
limitation FEF25e75%: rhoZ 0.30; pZ 0.020 and airway to
lung size FEF25e75%/FVC: rho Z 0.26; p Z 0.043).
Comparison of symptomatic and asymptomatic
subjects with AHR
The Table 2 describes the patients with AHR according to
the presence of asthmatic symptoms. Asthmatic patients
had similar levels of exhaled NO, but exhibited a lower lung
function and higher degrees of airway reactivity and
sensitivity.
We further evaluated in the whole population the
pathophysiology of AHR using a logistic regression model
with AHR as dependent variable and log of alveolar NO,
FEF25e75%, FEF25e75%/FVC and symptoms (asthma) as inde-
pendent variables that demonstrated that both alveolar NO
(p Z 0.048) and FEF25e75% (p Z 0.004) remained indepen-
dently associated with AHR (r2 of the model Z 0.18) while
FEF25e75%/FVC and symptoms were not independent
predictors of AHR (pZ 0.072 and pZ 0.066, respectively).
Discussion
The main result of this cross-sectional study is the sugges-
tion that airway reactivity is linked to some extent to
bronchiolar/alveolar NO (corrected for back diffusion) in
patients with nasal polyposis. The statistical significance of
the relationship is weak (w25% of variance of the model),
implying that other factors contribute to airway reactivity
Figure 2 Relationship between alveolar NO and airway
reactivity in patients with airway hyperresponsiveness. The X
axis is alveolar NO concentration (Calv,NO ppb, corrected for
axial diffusion), while the Y axis is airway reactivity (slope of
the doseeresponse curve of methacholine challenge test).




N Z 71 (54%)
Without AHR
N Z 61 (46%)
P value
Female (%) 81 (61) 39 (55) 42 (69) NS
Age, yrs 48  14 50  14 46  13 0.08
BMI, kg m2 24.5  3.9 24.1  3.7 24.9  4.0 0.27
Never-smokers, n (%) 78 42 36 NS
Ex-smokers, n (%) 35 19 16 NS
Current-smokers, n (%) 19 10 9 NS
Tobacco, Pack-year $ 16  12 19  15 14  9 0.14
Asthma, n (%) 16 (12) 15 (28) 1
age at asthma onset, years 17 [9e45] 18 [9e45] 12
Exhaled NO
linearitya, n 122 64 58 NS
FENO0.05, ppb 25.4 [14.2e34.6] 26.4 [14.8e44.5] 21.5 [14.1e31.4] 0.098
CalvNO, ppb 4.6 [2.2e8.3] 5.4 [2.8e10.7] 3.8 [1.4e6.9] 0.018
J’awNO, pL.s-1 1374 [652e2437] 1587 [538e3017] 1275 [793e1983] 0.59
PFT
FEV1, % predicted 100  19 94  21 106  14 0.0001
sVC, % predicted 102  17 100  18 109  13 0.004
FEV1/sVC 0.76  0.09 0.73  0.11 0.79  0.06 0.0006
FEF25e75, % predicted 79  30 69  31 91  26 <0.0001
FEF25e75%/FVC 0.73  0.28 0.67  0.32 0.79  0.21 0.013
R0 rs, cmH2O 3.27  1.66 3.57  1.87 2.91  1.29 0.024
R0 rs, % predicted 129  63 139  72 118  47 0.060
Response to DI, % increase þ6 [4 e þ19] þ13 [þ1 e þ24] þ4 [8 e þ13] 0.019
Methacholine challenge test
Reactivity (slope), %/mg 0.053 [0.015e0.117]
Sensitivity (PD10), mg 128 [48e317]
PD20, mg 372 [174e1325]
The P values are related to the comparisons of patients with and without AHR.
A dose of methacholine of 2.4 mg or less causing a 20% fall in FEV1 (PD20) was used to identify AHR.
FENO0.05 (ppb) denotes fractional exhaled nitric oxide obtained at a constant expiratory flow rate of 0.05 L/s.
a FENO0.05 has been obtained in the whole population, but the linearity of relationship between expiratory flow rate and NO output was
not observed for the whole population (122/132, 92%), accordingly to our previous results.11
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is related to both a higher degree of airway reactivity/
sensitivity and decreased airway to lung size ratio and/or
airway remodeling.
Airway reactivity and sensitivity are the two major
underlying mechanisms of AHR. In 1989, Sterk and Bel
reviewed the mechanisms of airway sensitivity and airway
reactivity.3 They proposed that airway sensitivity is deter-
mined by the strength of the stimulus that triggers the
airways to narrow. Determinants of airway sensitivity
include epithelial damage and malfunction, neural control,
inflammatory cell number/activity, interactions among
these factors, and altered metabolism or absorption of
inflammatory mediators. Accordingly, several studies
support the view of Sterk and Bel that the degree of cellular
inflammation, as measured by the sputum eosinophil count,
is related to airway sensitivity17 but conflict with the results
of others.18 Since eosinophilic airway inflammation and
exhaled NO are usually linked,7 a correlation between
exhaled NO and sensitivity should be expected. Neverthe-
less, the former relationship is weak, and the relationship
between FENO and AHR has inconsistently been demon-
strated.19e21 In our series, FENO measured at 0.05 L/s was
not significantly correlated with PD20 in the patients with
Table 2 Characteristics of the 71 patients with AHR according to the presence of asthmatic symptoms.
Characteristics With asthma
N Z 15 (21%)
Without asthma
N Z 56 (79%)
P valuea
Female (%) 10 (67) 22 (39) 0.081
Age, yrs 42  13 46  13 0.018
BMI, kg m2 24.3  4.3 24.1  3.6 0.79
Exhaled NO
FENO0.05, ppb 27.5 [19.7e44.1] 25.7 [12.4e51.9] 0.68
CalvNO, ppb 5.8 [4.3e14.8] 5.3 [2.6e9.5] 0.25
J’awNO, pL s
1 1558 [623e3173] 1587 [453e3003] 0.83
PFT
FEV1, % predicted 81  16 98  21 0.001
sVC, % predicted 97  18 100  18 0.56
FEV1/sVC 0.68  0.08 0.75  0.11 0.012
FEF25e75%, % predicted 46  18 75  31 0.0005
FEF25e75%/FVC 0.51  0.16 0.71  0.34 0.013
Response to DI#, % increase þ19 [þ1 e þ32] þ12 [0 e þ21] 0.31
Methacholine challenge test
Reactivity (slope), %/mg 0.186 [0.081e0.473] 0.035 [0.010e0.083] 0.001
Sensitivity (PD10), mg 48 [21e58] 171 [64e369] 0.004
PD20, mg 103 [43e174] 619 [202e1388] 0.0003
A dose of methacholine of 2.4 mg or less causing a 20% fall in FEV1 (PD20) was used to identify AHR.
FENO0.05 (ppb) denotes fractional exhaled nitric oxide obtained at a constant expiratory flow rate of 0.05 L/s.
a using Mann Whitney U test due to the restricted size of the group of asthmatic patients. The P values are related to the comparisons of
patients with and without asthma.
72 B. Mahut et al.AHR. At this expiratory flow rate, FENO mainly originates
from its bronchial source, which may explain this lack of
significance since no significant correlation was evidenced
between maximum NO flux from airways and airway sensi-
tivity. Furthermore, nasal polyposis constitutes a specific
setting in which the prevalence of non allergic asthma is
elevated.
As for airway reactivity, Sterk and Bel regarded this
variable to represent the responsiveness of the airways to
the stimulus given.3 Determinants of airway reactivity
include airway smooth muscle contractility, viscous and
elastic loads on muscle shortening, swelling of the airway
wall, and intralumenal exudate and secretions. To our best
knowledge this is the first study that shows a significant
relationship between bronchiolar/alveolar NO and airway
reactivity, which is relevant from a pathophysiological
point of view. Airway reactivity may constitute an intrinsic
characteristic of asthma disease, being linked to smooth
muscle cell physiology. We previously showed that NO
inhibition decreased the airway tone of ex vivo human
bronchi in COPD22 suggesting that NO may surprisingly be
involved in bronchoconstriction, which is further supported
by the recent demonstration of a link between bronchiolar/
alveolar NO and bronchodilator response in asthma.9 An
increase in bronchiolar/alveolar NO may be present in up to
25% of asthmatic patients.23 We also evidenced a relation-
ship between bronchiolar/alveolar NO and remodeling
(FEF25e75%),
7,24 suggesting that its increase may represent
a marker of severity rather than control. Accordingly, the
degree of AHR is usually in proportion to the severity of the
underlying asthma.25 Computational modeling of the
tracheobronchial tree has suggested that increased airway
wall thickness has the potential to cause increasedreactivity and maximal narrowing without changing sensi-
tivity,26 which may further explain the observed relation-
ship between reactivity and remodeling in our study.
Recent studies have emphasized to potential clinical rele-
vance of reactivity/sensitivity determination. For instance,
in patients with stable asthma, bronchial reactivity (but not
sensitivity) has been associated with health-related quality
of life, and it has also been shown that the adolescents with
asthma remission may show a significant decrease of
reactivity, whereas sensitivity was not changed.27,28
The relationship between an index of airway to lung size
as FEF25e75%/FVC and the degree of AHR is well-established
in the general population.2 Obviously, this index is a crude
assessment of airway to lung size ratio,29 which is also
sensitive to remodeling. Our results further suggest that
this relationship is also valid in the subgroup of patients
with nasal polyposis and AHR, and that this pathophysio-
logical link is associated with reactivity rather than sensi-
tivity to methacholine. We further show in the whole
population that AHR pathophysiology relies on both alveolar
NO and an index of airway size (FEF25e75%), while logically
the presence of symptoms (asthma) was not an indepen-
dent factor of AHR, logically.
Deep inspirations are known to exert strong beneficial
effects on the airways of healthy humans. These effects
appear to be of dual nature: bronchoprotective and bron-
chodilatory. The bronchoprotective effect of deep inspira-
tion is lost in asthma.30 It is also lost in individuals with
rhinitis and AHR, but no asthma.31 Therefore, it has been
postulated that the loss of bronchoprotection could mainly
be related to AHR.31 No relationship is evidenced in our
study between the bronchomotor effect of DI and both
exhaled NO (alveolar, bronchial) and AHR (reactivity,
Alveolar NO and airway reactivity 73sensitivity) parameters, but this bronchomotor effect was
related to an index of airway to lung size, thereby poten-
tially indirectly contributing to AHR.
Clinical perspectives
It has been shown that distal NO production is insensitive to
inhaled corticosteroid in asthma,32 which may explain the
non significant effect of steroid on AHR.14 Since the asso-
ciation of smaller airways and higher degree of AHR may
explain the occurrence of asthmatic symptoms (see Table
2), accordingly with the statement of Boulet,1 specific
therapies targeting bronchiolar/alveolar spaces could be
warranted.
Study limitations
First, the degree of significance of the observed relationships
are weak (rho values 0.35 to 0.40), which underlines that
other factors are involved, obviously. These relationships do
not imply causality, which may be inferred from experi-
mental studies.22 Tobacco smoking may have biased our
results to some extent, even if smoking history do not greatly
impact alveolar NO fraction.33 We only evaluated the bron-
chomotor response to DI, and not the bronchoprotective role
of DI, which could give different results. Given the small
number of patients with asthma (n Z 15), our study was
underpowered to confidently assess the potential con-
founding role of asthmatic patients on the relationship
between AHR and exhaled NO parameters. Finally, our
results have been obtained in a specific context, nasal pol-
yposis, and remain to be confirmed in a broader set of
patients with AHR. Nevertheless, our demonstration is
important since the presence of AHR constitutes a severity
factor in patients with nasal polyposis.34
In conclusion, in patients with nasal polyposis and airway
hyperresponsiveness, increased airway reactivity is associ-
ated with increased alveolar NO, suggesting that bronchi-
olar/alveolar lung inflammation may constitute one
intrinsic characteristic of asthma.
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